Concepts (220)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptor, Cannabinoid, CB1 | 11 | 2019 | 40 | 1.880 |
Why?
|
| Endocannabinoids | 9 | 2022 | 40 | 1.200 |
Why?
|
| Asthma | 10 | 2022 | 410 | 1.190 |
Why?
|
| Arachidonic Acids | 6 | 2017 | 25 | 1.070 |
Why?
|
| Cannabinoids | 8 | 2022 | 67 | 1.050 |
Why?
|
| Ethanol | 4 | 2019 | 221 | 0.940 |
Why?
|
| Receptor, Cannabinoid, CB2 | 6 | 2018 | 34 | 0.820 |
Why?
|
| Polyunsaturated Alkamides | 5 | 2017 | 15 | 0.720 |
Why?
|
| Anti-Asthmatic Agents | 6 | 2021 | 45 | 0.710 |
Why?
|
| Neurogenesis | 2 | 2018 | 64 | 0.630 |
Why?
|
| Receptors, Cannabinoid | 6 | 2022 | 27 | 0.620 |
Why?
|
| Matrix Metalloproteinases | 2 | 2009 | 49 | 0.570 |
Why?
|
| Zebrafish | 2 | 2019 | 146 | 0.460 |
Why?
|
| Signal Transduction | 9 | 2019 | 2111 | 0.450 |
Why?
|
| Hippocampus | 1 | 2018 | 591 | 0.440 |
Why?
|
| Genome-Wide Association Study | 5 | 2022 | 421 | 0.400 |
Why?
|
| GTP-Binding Proteins | 2 | 2002 | 58 | 0.380 |
Why?
|
| Nervous System | 1 | 2012 | 33 | 0.370 |
Why?
|
| Piperidines | 5 | 2022 | 80 | 0.330 |
Why?
|
| Pharmacogenetics | 2 | 2021 | 63 | 0.310 |
Why?
|
| Neovascularization, Physiologic | 2 | 2009 | 80 | 0.310 |
Why?
|
| Molecular Probes | 1 | 2009 | 23 | 0.300 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 2 | 2007 | 13 | 0.300 |
Why?
|
| Animals | 20 | 2022 | 16695 | 0.290 |
Why?
|
| Endothelial Cells | 3 | 2009 | 324 | 0.280 |
Why?
|
| Pyrazoles | 4 | 2018 | 93 | 0.280 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2021 | 62 | 0.260 |
Why?
|
| Nitric Oxide | 2 | 2007 | 381 | 0.250 |
Why?
|
| Cyclic AMP | 1 | 2006 | 135 | 0.240 |
Why?
|
| Receptors, Drug | 2 | 2002 | 57 | 0.240 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 2007 | 142 | 0.230 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 3 | 2022 | 55 | 0.230 |
Why?
|
| Lipopolysaccharides | 1 | 2006 | 235 | 0.230 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 979 | 0.220 |
Why?
|
| Glycerides | 2 | 2017 | 12 | 0.200 |
Why?
|
| Stroke | 1 | 2007 | 348 | 0.200 |
Why?
|
| Child | 9 | 2021 | 3381 | 0.200 |
Why?
|
| Muscle Relaxation | 1 | 2002 | 19 | 0.190 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 1554 | 0.190 |
Why?
|
| Macrophages | 1 | 2006 | 515 | 0.190 |
Why?
|
| Administration, Inhalation | 5 | 2021 | 92 | 0.190 |
Why?
|
| Rats | 6 | 2018 | 3701 | 0.180 |
Why?
|
| Epoxide Hydrolases | 1 | 2021 | 8 | 0.180 |
Why?
|
| Cyclopropanes | 1 | 2021 | 42 | 0.180 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2022 | 860 | 0.180 |
Why?
|
| Acetates | 1 | 2021 | 29 | 0.180 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2021 | 19 | 0.180 |
Why?
|
| Quinolines | 1 | 2021 | 76 | 0.170 |
Why?
|
| Sulfides | 1 | 2021 | 77 | 0.170 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2019 | 10 | 0.150 |
Why?
|
| Humans | 21 | 2022 | 42163 | 0.150 |
Why?
|
| Hedgehog Proteins | 1 | 2019 | 51 | 0.150 |
Why?
|
| GTPase-Activating Proteins | 1 | 2019 | 29 | 0.150 |
Why?
|
| Cytidine Deaminase | 1 | 2019 | 36 | 0.150 |
Why?
|
| Embryo, Nonmammalian | 1 | 2019 | 59 | 0.150 |
Why?
|
| Amidohydrolases | 2 | 2022 | 12 | 0.150 |
Why?
|
| Male | 12 | 2022 | 22779 | 0.140 |
Why?
|
| Zebrafish Proteins | 1 | 2019 | 55 | 0.140 |
Why?
|
| Carbamates | 1 | 2018 | 13 | 0.140 |
Why?
|
| AIDS Dementia Complex | 1 | 2019 | 116 | 0.140 |
Why?
|
| Child, Preschool | 5 | 2021 | 1516 | 0.140 |
Why?
|
| Ki-67 Antigen | 1 | 2018 | 34 | 0.140 |
Why?
|
| Naphthalenes | 3 | 2007 | 38 | 0.140 |
Why?
|
| Benzoxazines | 3 | 2007 | 46 | 0.140 |
Why?
|
| Morpholines | 3 | 2007 | 73 | 0.140 |
Why?
|
| Neuropeptides | 1 | 2018 | 63 | 0.140 |
Why?
|
| Drug Interactions | 1 | 2018 | 151 | 0.140 |
Why?
|
| Enzyme Inhibitors | 3 | 2022 | 457 | 0.140 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2015 | 95 | 0.130 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2018 | 95 | 0.130 |
Why?
|
| Piperazines | 1 | 2018 | 117 | 0.130 |
Why?
|
| Caspase 3 | 1 | 2018 | 226 | 0.130 |
Why?
|
| Young Adult | 7 | 2021 | 4936 | 0.130 |
Why?
|
| Cells, Cultured | 3 | 2017 | 1617 | 0.130 |
Why?
|
| Pertussis Toxin | 3 | 2007 | 25 | 0.130 |
Why?
|
| Cell Death | 1 | 2018 | 277 | 0.130 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2019 | 303 | 0.130 |
Why?
|
| Mice | 8 | 2022 | 6490 | 0.130 |
Why?
|
| Adolescent | 7 | 2021 | 5950 | 0.130 |
Why?
|
| Female | 12 | 2022 | 24018 | 0.120 |
Why?
|
| Genotype | 4 | 2021 | 796 | 0.120 |
Why?
|
| DNA-Binding Proteins | 1 | 2019 | 557 | 0.120 |
Why?
|
| Research Design | 1 | 2017 | 370 | 0.110 |
Why?
|
| Rabbits | 2 | 2007 | 292 | 0.110 |
Why?
|
| Neuroprotective Agents | 1 | 2017 | 267 | 0.110 |
Why?
|
| Spinal Cord Injuries | 1 | 2015 | 68 | 0.110 |
Why?
|
| Endothelium, Vascular | 2 | 2009 | 261 | 0.110 |
Why?
|
| Up-Regulation | 3 | 2019 | 534 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 415 | 0.100 |
Why?
|
| HIV-1 | 1 | 2019 | 747 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 4 | 2022 | 1804 | 0.100 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2013 | 6 | 0.100 |
Why?
|
| G-Protein-Coupled Receptor Kinases | 1 | 2013 | 7 | 0.100 |
Why?
|
| Arrestins | 1 | 2013 | 28 | 0.100 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2013 | 21 | 0.100 |
Why?
|
| Monoacylglycerol Lipases | 1 | 2012 | 2 | 0.100 |
Why?
|
| Membrane Microdomains | 1 | 2012 | 53 | 0.100 |
Why?
|
| Neutrophils | 1 | 2013 | 141 | 0.090 |
Why?
|
| Cyclooxygenase 2 | 1 | 2012 | 106 | 0.090 |
Why?
|
| Cell Proliferation | 1 | 2018 | 1420 | 0.090 |
Why?
|
| Cysteine | 1 | 2012 | 101 | 0.090 |
Why?
|
| Motor Neurons | 1 | 2012 | 88 | 0.090 |
Why?
|
| Neural Pathways | 1 | 2012 | 139 | 0.090 |
Why?
|
| Prosencephalon | 2 | 2012 | 34 | 0.090 |
Why?
|
| Cyclohexanols | 2 | 2007 | 7 | 0.080 |
Why?
|
| Neurons | 1 | 2017 | 1246 | 0.080 |
Why?
|
| Cell Membrane | 1 | 2012 | 400 | 0.080 |
Why?
|
| Cell Line | 3 | 2012 | 1416 | 0.080 |
Why?
|
| Azirines | 1 | 2009 | 2 | 0.080 |
Why?
|
| Photoaffinity Labels | 1 | 2009 | 3 | 0.080 |
Why?
|
| Azides | 1 | 2009 | 10 | 0.080 |
Why?
|
| Synaptic Transmission | 2 | 2022 | 156 | 0.070 |
Why?
|
| Phosphorylation | 2 | 2013 | 973 | 0.070 |
Why?
|
| Risk | 2 | 2021 | 289 | 0.070 |
Why?
|
| Mice, Transgenic | 2 | 2022 | 658 | 0.070 |
Why?
|
| Fluorescent Dyes | 1 | 2009 | 182 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2021 | 587 | 0.070 |
Why?
|
| HIV Infections | 1 | 2022 | 2535 | 0.070 |
Why?
|
| Amino Acid Sequence | 3 | 2007 | 1188 | 0.070 |
Why?
|
| Angiostatins | 1 | 2007 | 2 | 0.070 |
Why?
|
| Mitochondrial Proton-Translocating ATPases | 1 | 2007 | 6 | 0.070 |
Why?
|
| Resorcinols | 1 | 2007 | 4 | 0.070 |
Why?
|
| Leucine | 1 | 2007 | 30 | 0.070 |
Why?
|
| Molecular Sequence Data | 3 | 2007 | 1559 | 0.070 |
Why?
|
| Benzofurans | 1 | 2007 | 22 | 0.070 |
Why?
|
| Guanylate Cyclase | 1 | 2007 | 21 | 0.070 |
Why?
|
| Cardiovascular Agents | 1 | 2007 | 24 | 0.070 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2006 | 20 | 0.060 |
Why?
|
| Cycloheximide | 1 | 2006 | 30 | 0.060 |
Why?
|
| Chromones | 1 | 2007 | 53 | 0.060 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2007 | 66 | 0.060 |
Why?
|
| Reactive Nitrogen Species | 1 | 2006 | 10 | 0.060 |
Why?
|
| Brain Diseases | 1 | 2006 | 31 | 0.060 |
Why?
|
| Membrane Proteins | 2 | 2007 | 548 | 0.060 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2006 | 74 | 0.060 |
Why?
|
| Pregnancy | 1 | 2012 | 1737 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 1020 | 0.060 |
Why?
|
| Carrier Proteins | 1 | 2007 | 318 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 301 | 0.060 |
Why?
|
| Brain Ischemia | 1 | 2007 | 196 | 0.060 |
Why?
|
| Hospitalization | 2 | 2021 | 482 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2007 | 297 | 0.060 |
Why?
|
| Adult | 4 | 2021 | 13458 | 0.060 |
Why?
|
| Microglia | 1 | 2006 | 204 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 1112 | 0.050 |
Why?
|
| Ligands | 1 | 2005 | 387 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2006 | 518 | 0.050 |
Why?
|
| Models, Molecular | 2 | 2007 | 875 | 0.050 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2002 | 12 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2013 | 2598 | 0.050 |
Why?
|
| Receptors, Calcitonin Gene-Related Peptide | 1 | 2002 | 2 | 0.050 |
Why?
|
| Disease Progression | 2 | 2017 | 661 | 0.050 |
Why?
|
| Virulence Factors, Bordetella | 1 | 2002 | 5 | 0.050 |
Why?
|
| Calcium Channels | 1 | 2002 | 74 | 0.050 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2002 | 36 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2002 | 136 | 0.050 |
Why?
|
| Capsaicin | 1 | 2002 | 28 | 0.050 |
Why?
|
| Gap Junctions | 1 | 2002 | 49 | 0.050 |
Why?
|
| Leukotriene Antagonists | 1 | 2021 | 1 | 0.050 |
Why?
|
| Nitric Oxide Synthase | 1 | 2002 | 134 | 0.050 |
Why?
|
| Europe | 1 | 2021 | 114 | 0.040 |
Why?
|
| Age of Onset | 1 | 2021 | 115 | 0.040 |
Why?
|
| Aorta | 1 | 2002 | 197 | 0.040 |
Why?
|
| Pyridines | 1 | 2022 | 134 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 3077 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2021 | 200 | 0.040 |
Why?
|
| Alleles | 1 | 2021 | 352 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2021 | 487 | 0.040 |
Why?
|
| Risk Factors | 2 | 2020 | 3942 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2002 | 633 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2022 | 727 | 0.040 |
Why?
|
| Psychomotor Performance | 1 | 2019 | 156 | 0.040 |
Why?
|
| Quality of Life | 1 | 2022 | 599 | 0.030 |
Why?
|
| International Cooperation | 1 | 2017 | 51 | 0.030 |
Why?
|
| Phenotype | 1 | 2020 | 774 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2020 | 845 | 0.030 |
Why?
|
| Prefrontal Cortex | 1 | 2017 | 160 | 0.030 |
Why?
|
| Middle Aged | 2 | 2021 | 11819 | 0.030 |
Why?
|
| Calcium | 1 | 2017 | 487 | 0.030 |
Why?
|
| Spinal Cord | 1 | 2015 | 109 | 0.030 |
Why?
|
| Logistic Models | 1 | 2017 | 1001 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2017 | 960 | 0.030 |
Why?
|
| Cell Survival | 1 | 2017 | 934 | 0.030 |
Why?
|
| Infant | 1 | 2017 | 1143 | 0.030 |
Why?
|
| Phenylurea Compounds | 1 | 2013 | 18 | 0.030 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2013 | 51 | 0.030 |
Why?
|
| Chemotaxis | 1 | 2013 | 66 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2017 | 1586 | 0.020 |
Why?
|
| Wound Healing | 1 | 2013 | 82 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2016 | 916 | 0.020 |
Why?
|
| Lipoylation | 1 | 2012 | 17 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2013 | 137 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 233 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2012 | 207 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2013 | 452 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2013 | 1010 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 479 | 0.020 |
Why?
|
| Corneal Neovascularization | 1 | 2007 | 6 | 0.020 |
Why?
|
| Binding Sites, Antibody | 1 | 2007 | 19 | 0.020 |
Why?
|
| Chorioallantoic Membrane | 1 | 2007 | 11 | 0.020 |
Why?
|
| Epitope Mapping | 1 | 2007 | 31 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2007 | 92 | 0.020 |
Why?
|
| Biomimetic Materials | 1 | 2007 | 24 | 0.020 |
Why?
|
| Mutation | 1 | 2012 | 1169 | 0.020 |
Why?
|
| Catalytic Domain | 1 | 2007 | 118 | 0.020 |
Why?
|
| Analgesics | 1 | 2007 | 55 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2007 | 185 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2007 | 256 | 0.020 |
Why?
|
| Lipid Bilayers | 1 | 2007 | 56 | 0.020 |
Why?
|
| Vascular Diseases | 1 | 2007 | 33 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2007 | 122 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2007 | 205 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2007 | 427 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2007 | 385 | 0.020 |
Why?
|
| Cattle | 1 | 2007 | 505 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2007 | 686 | 0.010 |
Why?
|
| Drug Design | 1 | 2007 | 183 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 249 | 0.010 |
Why?
|
| Protein Binding | 1 | 2007 | 1076 | 0.010 |
Why?
|
| Brain | 1 | 2006 | 1452 | 0.010 |
Why?
|